Skip to main content
Fig. 11 | Cancer Cell International

Fig. 11

From: Transcription factors-related molecular subtypes and risk prognostic model: exploring the immunogenicity landscape and potential drug targets in hepatocellular carcinoma

Fig. 11

Changes in the expression levels of core TFs under trametinib treatment. A, C Cell survival rates were examined by the CCK-8 assay. HepG2 (A) and Huh7 (C) cells were treated with different concentrations of trametinib. After 24 h, cell viability was examined using the CCK-8 assay. B, D Expression of core TFs in HCC cells was examined by RT-PCR. HepG2 (B) and Huh7 (D) cells were treated with different concentrations of trametinib for 24 h. Total RNA was extracted from trametinib-treated cells. *p < 0.05, **p < 0.01, ***p < 0.001

Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us